Immunocore could be just weeks away from gaining US approval for its immunotherapy, tebentafusp (IMCgp100), which would make it the first T-cell receptor (TCR) therapy to reach the market.
TCR therapies have the potential to overcome limitations in checkpoint inhibitors and CAR-Ts, being able to take any T-cell in the body and transform it into a killer cell against cancer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?